Contact
Sitemap
Home
Rheumatoid Arthritis is a chronic multisystem disease of unknown cause. The characteristic feature of RA is persistent inflammatory synovitis, usually involving peripheral joints in a symmetric distribution. The potential of the synovial inflammation to cause cartilage damage and bone erosion and subsequent adverse changes in integrity of the joint is the main feature of this disease.
The prevalence of RA is approximately 1 % of the population with woman getting affected three times more than men.
The persistence of inflammation leads to progressive damage of the joints. The rheumatoid synovium is characterized by the presence of a number of secreted Cytokines / Chemokines from activated lymphocytes, macrophages and fibroblasts. The local production of the Cytokines and Chemokines appear to account for many of the pathological and clinical manifestations. Significant damage is caused by TNF.alfa, IL-1 and IL-6.
The Indus candidate not only reverses the cause of the inflammation but also modifies the disease (DMARD). This drug candidate is developed on the novel target of MAPK P 38 inhibition.
The prevalence of RA is approximately 1 % of the population with woman getting affected three times more than men.
The persistence of inflammation leads to progressive damage of the joints. The rheumatoid synovium is characterized by the presence of a number of secreted Cytokines / Chemokines from activated lymphocytes, macrophages and fibroblasts. The local production of the Cytokines and Chemokines appear to account for many of the pathological and clinical manifestations. Significant damage is caused by TNF.alfa, IL-1 and IL-6.
The Indus candidate not only reverses the cause of the inflammation but also modifies the disease (DMARD). This drug candidate is developed on the novel target of MAPK P 38 inhibition.
